决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Immunological Profile for Patients Treated With CAR-T Cells
Immunological Profile for Patients Treated With CAR-T Cells
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
⚠ 该试验的登记信息已有 60 个月未更新, 页面上显示的「尚未开始招募」可能已经失效。联系研究中心之前,建议先到 ClinicalTrials.gov 核对登记原文的最新状态与联系方式。
这是一项分期未标注的注册临床试验,评估细胞治疗用于肿瘤的安全性、可行性及初步疗效。当前状态:尚未开始招募。计划入组 500 例。试验地点:欧洲 · 马赛(共 1 个中心)。登记号:NCT05054231。
不限性别 · ≥ 18 Years
纳入标准: * 年龄 ≥ 18岁 * 计划在上市许可范围内注射CAR-T 细胞 * 签署知情同意书 * 法国社会保险归属 排除标准: * 孕妇,或育龄期女性(未采取医学上可接受的避孕措施)或哺乳期女性。 * 处于紧急情况的患者,受法律保护的成年人(处于监护、保佐或司法保护下的患者)或无法给出同意的患者 * 因地理、社会或心理原因无法遵守试验医学随访
Inclusion Criteria: * Age ≥ 18 years * Planned injection of CAR-T cells within the scope of marketing authorization * Signed informed consent * French social security affiliation Exclusion Criteria: * Pregnant women, or women of childbearing potential (without medically acceptable contraception) or breastfeeding women. * Patient in emergency situation, adult under legal protection (patient placed under tutorship, curatorship, or judicial protection) or unable to give his consent * Impossibility to comply with trial medical follow-up for geographic, social or psychological reasons
以上为辅助阅读译文。是否适合入组须由主治医生判断,最终以登记平台与研究者确认为准。
主要终点:Correlation between serum markers and adverse events at 1 year of the CAR-T cells infusion · Serum concentration of cytokines in relation to adverse events · 1 year after T cells infusion
次要终点:CAR-T cells rate from infusion to one year after CAR-T cells infusion;Number of participants with a relapse;Number of participants with a cytokine release syndrome
以上邮箱 / 电话是登记库里的申办方联系方式,通常不直达某家医院。中国中心的联系方式请以医院或登记平台最新公示为准。
在Si-CART研究的框架内,将从接受CAR-T 细胞治疗的患者中采集血液:在细胞注射前(第(D)-6天和D0天细胞输注前),输注后第D3、D5、D7、D9、D11、D14、D18、D21天,以及注射后第(M)2个月和第M12个月。 如果进行脑脊液分析腰椎穿刺,还将采集脑脊液样本。
In the frame of Si-CART study, blood will be collected from patients treated with CAR-T cells: before (at Day (D)-6 and D0 before cells injection), post infusion at D3, D5,D7, D9, D11, D14, D18, D 21, Month (M) 2 and M12 post injection. A cerebrospinal fluid sample will also be collected if a Cerebrospinal Fluid Analysis Lumbar puncture is performed
MEMBER ACCOUNT
登录成功会直接打开下一页。